Hereditary spherocytosis differential diagnosis

Revision as of 17:15, 2 August 2018 by Amar Morani (talk | contribs)
Jump to navigation Jump to search

Hereditary spherocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary spherocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary spherocytosis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary spherocytosis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary spherocytosis differential diagnosis

CDC on Hereditary spherocytosis differential diagnosis

Hereditary spherocytosis differential diagnosis in the news

Blogs on Hereditary spherocytosis differential diagnosis

Directions to Hospitals Treating Hereditary spherocytosis

Risk calculators and risk factors for Hereditary spherocytosis differential diagnosis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The differential diagnosis of HS includes a number of other hemolytic anemias with spherocytes on the peripheral blood smear:

Differential diagnosis

Glucose-6-phosphate dehydrogenase deficiency:

Infantile pyknocytosis:

  • Infantile pyknocytosis is a disorder of unknown etiology in which RBCs become hyperdense and dehydrated [111]. Like HS, this condition presents in neonates with anemia and an increased mean corpuscular hemoglobin concentration (MCHC). Unlike HS, the RBCs have irregular borders and varying numbers of projections, and the condition resolves spontaneously during the first year of life (typically, six to nine months after birth) without intervention.

Congenital dyserythropoietic anemia (CDA)

  • CDA type II is a group of inherited anemias caused by one of several gene variants that results in abnormal RBC production in the bone marrow. Like HS, some individuals may have significant hemolysis and/or splenomegaly, and like HS, some specialized tests such as EMA binding may be positive. Unlike HS, individuals with one of the CDAs are likely to have characteristic morphology of RBC precursors in the bone marrow, and the reticulocyte count is usually lower in the CDAs [80]

Autoimmune hemolytic anemias:

  • AIHA, in which autoantibodies directed against self-RBC antigens lead to hemolysis, is a common cause of hemolysis and/or anemia, especially in adults. Warm AIHA associated with an underlying disorder such as systemic lupus erythematosus (SLE) or without an underlying disorder is more common than cold AIHA, which is typically triggered by an infection such as infectious mononucleosis. Like HS, patients can have anemia and/or hemolysis of variable severity and abundant spherocytes on the peripheral blood smear. Unlike HS, in AIHA, the Coombs test is typically positive, there is not family history of hemolytic anemia, and prior complete blood counts (CBCs) will show a normal hemoglobin level and reticulocyte count.

Other inherited hemolytic anemias :

  • Other inherited RBC membrane disorders include hereditary elliptocytosis (HE) (picture 3) and elliptocytosis variants (eg, Southeast Asian ovalocytosis [SAO], hereditary pyropoikilocytosis [HPP] (picture 4)), hereditary stomatocytosis (HSt), and hereditary xerocytosis (HX) (algorithm 1). RBC enzyme disorders include glucose-6-phosphate dehydrogenase (G6PD) deficiency, pyruvate kinase (PK) deficiency, and other rarer metabolic disorders. Like HS, these present with variable degrees of anemia and hemolysis and can be diagnosed at any age. Unlike the other disorders, G6PD deficiency typically presents with more discreet episodes of hemolysis after exposure to oxidant drugs. Unlike the other membrane disorders, which each have distinctive morphologies on the blood smear, and the enzyme disorders, which typically have nonspecific findings (eg, mild reticulocytosis), HS is characterized by spherocytosis as the predominant morphology.

Hemolytic disease of the fetus and newborn (HDFN):

  • Neonates may present with severe HDFN (also called neonatal alloimmune hemolytic anemia), which is caused by maternal antibodies that cross the placenta and recognize foreign fetal RBC antigens, leading to alloimmune hemolysis. Like HS, neonates can present with severe jaundice and anemia requiring aggressive treatment, and like HS, HDFN can be associated with abundant spherocytes on the blood smear. Unlike HS, HDFN is a transient condition that resolves after the maternal antibodies are cleared, and HDFN is characterized by positive Coombs testing, which typically reveals the alloantibodies on fetal RBCs, as well as evidence of an immunologically significant discordance between maternal and neonatal blood type.

References

Template:WH Template:WS